What is the Drug-Resistant Tuberculosis Treatment Market?

The Drug-Resistant Tuberculosis Treatment Market is a sector focused on providing medications and therapies to combat tuberculosis strains that have become resistant to standard treatment regimens.

How big is the Drug-Resistant Tuberculosis Treatment Market?

The global Drug-Resistant Tuberculosis Treatment Market size was estimated at USD 1,117.1 Million in 2023 and is expected to reach USD 1,802.4 Million in 2033.

What is the Drug-Resistant Tuberculosis Treatment Market growth?

The global Drug-Resistant Tuberculosis Treatment Market is expected to grow at a compound annual growth rate of 4.9%. From 2023 To 2033

Who are the key companies/players in the Drug-Resistant Tuberculosis Treatment Market?

Some of the key players in the Drug-Resistant Tuberculosis Treatment Markets are Sanofi SA, Novartis AG , Endo International Plc, CMP Pharma Inc. , STI Pharma LLC, Akorn Incorporated, Lupin , Johnson & Johnson Services Inc., Macleods Pharmaceuticals Ltd., Pfizer Inc., Hikma Pharmaceuticals PLC.

Which region dominates the market currently?

North America holds the largest market share, with 37% and USD 413.3 million in market revenue in 2023, primarily due to the rising prevalence of tuberculosis cases and the presence of key players.

What factors drive the growth of the Drug-Resistant Tuberculosis Treatment Market?

Market growth is driven by the increasing prevalence of drug-resistant tuberculosis cases, investments in research and development for new treatments, and the presence of key pharmaceutical companies.

What role do private organizations play in the market's growth?

Private organizations organize educational campaigns to raise awareness about TB diagnosis, prevention, and available treatment options, contributing to the growth of the Drug-Resistant Tuberculosis Treatment industry.

Global Drug-Resistant Tuberculosis Treatment Market By Drug Class (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Other Drug Classes) By Disease Type (Active TB, Latent TB) By Treatment Type (First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Feb 2024
Report ID: 84849
Number of Pages: 368
Format:

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
  - 1.4. Key Analysis
  - 1.5. Key Findings by Major Segments
  - 1.6. Top strategies by Major Players
- 2. Global Drug-Resistant Tuberculosis Treatment Overview
  - 2.1. Drug-Resistant Tuberculosis Treatment Dynamics
    
    2.1.1. Drivers
    
    2.1.2. Opportunities
    
    2.1.2. Restraints
    
    2.1.4. Challenges
  - 2.2. Macro-economic Factors
  - 2.3. Regulatory Framework
  - 2.4. Market Investment Feasibility Index
  - 2.5. PEST Analysis
  - 2.6. PORTER’S Five Force Analysis
  - 2.7. Drivers & Restraints Impact Analysis
  - 2.8. Industry Chain Analysis
  - 2.9. Cost Structure Analysis
  - 2.10. Marketing Strategy
  - 2.11. Russia-Ukraine War Impact Analysis
  - 2.12. Opportunity Map Analysis
  - 2.13. Market Competition Scenario Analysis
  - 2.14. Product Life Cycle Analysis
  - 2.15. Opportunity Orbits
  - 2.16. Manufacturer Intensity Map
  - 2.17. Major Companies sales by Value & Volume
- 3. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 3.1. Global Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
  - 3.2. Global Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
  - 3.3. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
    
    3.3.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
    
    3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
    
    3.3.3. Amoxicillin/Clavulanate
    
    3.3.4. Bedaquiline
    
    3.3.5. Carbapenems with Clavulanic Acid
    
    3.3.6. Clofazimine
    
    3.3.7. Cycloserine
    
    3.3.8. Delamanid
    
    3.3.9. Ethambutol
    
    3.3.10. Ethionamide and Prothionamide
    
    3.3.11. Other Drug Classes
  - 3.4. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
    
    3.4.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
    
    3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
    
    3.4.3. Multidrug-Resistant TB (MDR TB)
    
    3.4.4. Extensively Drug-Resistant TB (XDR TB)
  - 3.5. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
    
    3.5.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
    
    3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
    
    3.5.3. First-Line Anti-TB Drugs
    
    3.5.4. Second-Line Anti-TB Drugs
    
    3.5.5. Others Treatment Types
  - 3.6. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    
    3.6.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
    
    3.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    
    3.6.3. Hospital Pharmacies
    
    3.6.4. Online Pharmacies
    
    3.6.5. Retail Pharmacies
    
    3.6.6. Other Distribution Channels
- 4. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 4.1. North America Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
  - 4.2. North America Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
  - 4.3. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
    
    4.3.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
    
    4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
    
    4.3.3. Amoxicillin/Clavulanate
    
    4.3.4. Bedaquiline
    
    4.3.5. Carbapenems with Clavulanic Acid
    
    4.3.6. Clofazimine
    
    4.3.7. Cycloserine
    
    4.3.8. Delamanid
    
    4.3.9. Ethambutol
    
    4.3.10. Ethionamide and Prothionamide
    
    4.3.11. Other Drug Classes
  - 4.4. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
    
    4.4.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
    
    4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
    
    4.4.3. Multidrug-Resistant TB (MDR TB)
    
    4.4.4. Extensively Drug-Resistant TB (XDR TB)
  - 4.5. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
    
    4.5.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
    
    4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
    
    4.5.3. First-Line Anti-TB Drugs
    
    4.5.4. Second-Line Anti-TB Drugs
    
    4.5.5. Others Treatment Types
  - 4.6. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    
    4.6.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
    
    4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    
    4.6.3. Hospital Pharmacies
    
    4.6.4. Online Pharmacies
    
    4.6.5. Retail Pharmacies
    
    4.6.6. Other Distribution Channels
  - 4.7. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    4.7.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
    
    4.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    4.7.2.1. U.S.
    
    4.7.2.2. Canada
    
    4.7.2.3. Mexico
- 5. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 5.1. Europe Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
  - 5.2. Europe Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
  - 5.3. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
    
    5.3.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
    
    5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
    
    5.3.3. Amoxicillin/Clavulanate
    
    5.3.4. Bedaquiline
    
    5.3.5. Carbapenems with Clavulanic Acid
    
    5.3.6. Clofazimine
    
    5.3.7. Cycloserine
    
    5.3.8. Delamanid
    
    5.3.9. Ethambutol
    
    5.3.10. Ethionamide and Prothionamide
    
    5.3.11. Other Drug Classes
  - 5.4. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
    
    5.4.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
    
    5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
    
    5.4.3. Multidrug-Resistant TB (MDR TB)
    
    5.4.4. Extensively Drug-Resistant TB (XDR TB)
  - 5.5. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
    
    5.5.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
    
    5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
    
    5.5.3. First-Line Anti-TB Drugs
    
    5.5.4. Second-Line Anti-TB Drugs
    
    5.5.5. Others Treatment Types
  - 5.6. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    
    5.6.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
    
    5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    
    5.6.3. Hospital Pharmacies
    
    5.6.4. Online Pharmacies
    
    5.6.5. Retail Pharmacies
    
    5.6.6. Other Distribution Channels
  - 5.7. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    5.7.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
    
    5.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    5.7.2.1. U.K.
    
    5.7.2.2. Germany
    
    5.7.2.3. France
    
    5.7.2.4. Spain
    
    5.7.2.5. Italy
    
    5.7.2.6. Russia
    
    5.7.2.7. Rest of Europe
- 6. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 6.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
  - 6.2. Asia-Pacific Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
  - 6.3. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
    
    6.3.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
    
    6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
    
    6.3.3. Amoxicillin/Clavulanate
    
    6.3.4. Bedaquiline
    
    6.3.5. Carbapenems with Clavulanic Acid
    
    6.3.6. Clofazimine
    
    6.3.7. Cycloserine
    
    6.3.8. Delamanid
    
    6.3.9. Ethambutol
    
    6.3.10. Ethionamide and Prothionamide
    
    6.3.11. Other Drug Classes
  - 6.4. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
    
    6.4.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
    
    6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
    
    6.4.3. Multidrug-Resistant TB (MDR TB)
    
    6.4.4. Extensively Drug-Resistant TB (XDR TB)
  - 6.5. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
    
    6.5.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
    
    6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
    
    6.5.3. First-Line Anti-TB Drugs
    
    6.5.4. Second-Line Anti-TB Drugs
    
    6.5.5. Others Treatment Types
  - 6.6. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    
    6.6.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
    
    6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    
    6.6.3. Hospital Pharmacies
    
    6.6.4. Online Pharmacies
    
    6.6.5. Retail Pharmacies
    
    6.6.6. Other Distribution Channels
  - 6.7. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    6.7.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
    
    6.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    6.7.2.1. China
    
    6.7.2.2. Japan
    
    6.7.2.3. South Korea
    
    6.7.2.4. India
    
    6.7.2.5. Rest of Asia-Pacific
- 7. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 7.1. South America Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
  - 7.2. South America Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
  - 7.3. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
    
    7.3.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
    
    7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
    
    7.3.3. Amoxicillin/Clavulanate
    
    7.3.4. Bedaquiline
    
    7.3.5. Carbapenems with Clavulanic Acid
    
    7.3.6. Clofazimine
    
    7.3.7. Cycloserine
    
    7.3.8. Delamanid
    
    7.3.9. Ethambutol
    
    7.3.10. Ethionamide and Prothionamide
    
    7.3.11. Other Drug Classes
  - 7.4. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
    
    7.4.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
    
    7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
    
    7.4.3. Multidrug-Resistant TB (MDR TB)
    
    7.4.4. Extensively Drug-Resistant TB (XDR TB)
  - 7.5. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
    
    7.5.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
    
    7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
    
    7.5.3. First-Line Anti-TB Drugs
    
    7.5.4. Second-Line Anti-TB Drugs
    
    7.5.5. Others Treatment Types
  - 7.6. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    
    7.6.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
    
    7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    
    7.6.3. Hospital Pharmacies
    
    7.6.4. Online Pharmacies
    
    7.6.5. Retail Pharmacies
    
    7.6.6. Other Distribution Channels
  - 7.7. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    7.7.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
    
    7.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    7.7.2.1. Brazil
    
    7.7.2.2. Argentina
    
    7.7.2.3. Rest of South America
- 8. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 8.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
  - 8.2. Middle East and Africa Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
  - 8.3. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
    
    8.3.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
    
    8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
    
    8.3.3. Amoxicillin/Clavulanate
    
    8.3.4. Bedaquiline
    
    8.3.5. Carbapenems with Clavulanic Acid
    
    8.3.6. Clofazimine
    
    8.3.7. Cycloserine
    
    8.3.8. Delamanid
    
    8.3.9. Ethambutol
    
    8.3.10. Ethionamide and Prothionamide
    
    8.3.11. Other Drug Classes
  - 8.4. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
    
    8.4.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
    
    8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
    
    8.4.3. Multidrug-Resistant TB (MDR TB)
    
    8.4.4. Extensively Drug-Resistant TB (XDR TB)
  - 8.5. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
    
    8.5.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
    
    8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
    
    8.5.3. First-Line Anti-TB Drugs
    
    8.5.4. Second-Line Anti-TB Drugs
    
    8.5.5. Others Treatment Types
  - 8.6. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    
    8.6.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
    
    8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    
    8.6.3. Hospital Pharmacies
    
    8.6.4. Online Pharmacies
    
    8.6.5. Retail Pharmacies
    
    8.6.6. Other Distribution Channels
  - 8.7. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    8.7.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
    
    8.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    8.7.2.1. GCC
    
    8.7.2.2. Israel
    
    8.7.2.3. South Africa
    
    8.7.2.4. Rest of MEA
- 9. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Region , 2016-2032
  - 9.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Region : Introduction
  - 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
    
    9.2.1. North America
    
    9.2.2. Europe
    
    9.2.3. Asia-Pacific
    
    9.2.4. South America
    
    9.2.5. Middle East and Africa
- 10. Global Drug-Resistant Tuberculosis Treatment Competitive Landscape, Market Share Analysis, and Company Profiles
  - 10.1. Market Share Analysis
  - 10.2. Company Profiles
  - 10.3. Sanofi SA (France)
    
    10.3.1. Company Overview
    
    10.3.2. Financial Highlights
    
    10.3.3. Product Portfolio
    
    10.3.4. SWOT Analysis
    
    10.3.5. Key Strategies and Developments
  - 10.4. Novartis AG (Switzerland)
    
    10.4.1. Company Overview
    
    10.4.2. Financial Highlights
    
    10.4.3. Product Portfolio
    
    10.4.4. SWOT Analysis
    
    10.4.5. Key Strategies and Developments
  - 10.5. Endo International Plc (Ireland)
    
    10.5.1. Company Overview
    
    10.5.2. Financial Highlights
    
    10.5.3. Product Portfolio
    
    10.5.4. SWOT Analysis
    
    10.5.5. Key Strategies and Developments
  - 10.6. CMP Pharma Inc. ((US$ Mn & Units)ed States)
    
    10.6.1. Company Overview
    
    10.6.2. Financial Highlights
    
    10.6.3. Product Portfolio
    
    10.6.4. SWOT Analysis
    
    10.6.5. Key Strategies and Developments
  - 10.7. STI Pharma LLC ((US$ Mn & Units)ed States)
    
    10.7.1. Company Overview
    
    10.7.2. Financial Highlights
    
    10.7.3. Product Portfolio
    
    10.7.4. SWOT Analysis
    
    10.7.5. Key Strategies and Developments
  - 10.8. Akorn Incorporated ((US$ Mn & Units)ed States)
    
    10.8.1. Company Overview
    
    10.8.2. Financial Highlights
    
    10.8.3. Product Portfolio
    
    10.8.4. SWOT Analysis
    
    10.8.5. Key Strategies and Developments
  - 10.9. Lupin (India)
    
    10.9.1. Company Overview
    
    10.9.2. Financial Highlights
    
    10.9.3. Product Portfolio
    
    10.9.4. SWOT Analysis
    
    10.9.5. Key Strategies and Developments
  - 10.10. Johnson & Johnson Services Inc. ((US$ Mn & Units)ed States)
    
    10.10.1. Company Overview
    
    10.10.2. Financial Highlights
    
    10.10.3. Product Portfolio
    
    10.10.4. SWOT Analysis
    
    10.10.5. Key Strategies and Developments
  - 10.11. Macleods Pharmaceuticals Ltd. (India)
    
    10.11.1. Company Overview
    
    10.11.2. Financial Highlights
    
    10.11.3. Product Portfolio
    
    10.11.4. SWOT Analysis
    
    10.11.5. Key Strategies and Developments
  - 10.12. Pfizer Inc. ((US$ Mn & Units)ed States)
    
    10.12.1. Company Overview
    
    10.12.2. Financial Highlights
    
    10.12.3. Product Portfolio
    
    10.12.4. SWOT Analysis
    
    10.12.5. Key Strategies and Developments
  - 10.13. Hikma Pharmaceuticals PLC ((US$ Mn & Units)ed Kingdom)
    
    10.13.1. Company Overview
    
    10.13.2. Financial Highlights
    
    10.13.3. Product Portfolio
    
    10.13.4. SWOT Analysis
    
    10.13.5. Key Strategies and Developments
  - 10.14. Others.
    
    10.14.1. Company Overview
    
    10.14.2. Financial Highlights
    
    10.14.3. Product Portfolio
    
    10.14.4. SWOT Analysis
    
    10.14.5. Key Strategies and Developments
- 11. Assumptions and Acronyms
- 12. Research Methodology
- 13. Contact
- List of Figures
  - Figure 1: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classes in 2022
  - Figure 2: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
  - Figure 3: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
  - Figure 4: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
  - Figure 5: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
  - Figure 6: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
  - Figure 7: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 8: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 9: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Region in 2022
  - Figure 10: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Region, 2016-2032
  - Figure 11: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 12: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Figure 13: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Figure 14: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Figure 15: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Figure 16: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 17: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Figure 18: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Figure 19: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Figure 20: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Figure 21: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 22: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Region (2016-2032)
  - Figure 23: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Figure 24: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Figure 25: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Figure 26: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 27: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
  - Figure 28: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
  - Figure 29: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
  - Figure 30: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
  - Figure 31: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
  - Figure 32: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
  - Figure 33: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 34: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 35: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 36: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 37: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 38: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 39: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Figure 40: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Figure 41: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Figure 42: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 43: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 44: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Figure 45: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Figure 46: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Figure 47: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 48: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Figure 49: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Figure 50: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Figure 51: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Figure 52: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 53: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
  - Figure 54: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
  - Figure 55: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
  - Figure 56: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
  - Figure 57: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
  - Figure 58: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
  - Figure 59: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 60: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 61: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 62: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 63: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 64: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 65: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Figure 66: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Figure 67: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Figure 68: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 69: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 70: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Figure 71: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Figure 72: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Figure 73: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 74: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Figure 75: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Figure 76: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Figure 77: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Figure 78: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 79: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
  - Figure 80: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
  - Figure 81: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
  - Figure 82: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
  - Figure 83: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
  - Figure 84: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
  - Figure 85: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 86: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 87: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 88: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 89: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 90: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 91: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Figure 92: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Figure 93: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Figure 94: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 95: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 96: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Figure 97: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Figure 98: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Figure 99: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 100: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Figure 101: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Figure 102: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Figure 103: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Figure 104: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 105: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
  - Figure 106: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
  - Figure 107: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
  - Figure 108: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
  - Figure 109: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
  - Figure 110: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
  - Figure 111: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 112: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 113: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 114: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 115: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 116: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 117: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Figure 118: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Figure 119: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Figure 120: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 121: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 122: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Figure 123: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Figure 124: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Figure 125: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 126: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Figure 127: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Figure 128: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Figure 129: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Figure 130: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 131: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
  - Figure 132: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
  - Figure 133: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
  - Figure 134: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
  - Figure 135: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
  - Figure 136: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
  - Figure 137: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 138: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 139: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 140: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 141: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 142: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 143: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Figure 144: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Figure 145: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Figure 146: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 147: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 148: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Figure 149: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Figure 150: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Figure 151: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 152: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Figure 153: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Figure 154: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Figure 155: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Figure 156: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
- List of Tables
  - Table 1: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
  - Table 2: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
  - Table 3: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
  - Table 4: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
  - Table 5: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 6: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 7: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 8: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Table 9: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Table 10: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Table 11: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 12: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Table 13: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Table 14: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Table 15: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Table 16: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 17: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Region (2016-2032)
  - Table 18: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Table 19: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Table 20: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Table 21: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Table 22: North America Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
  - Table 23: North America Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
  - Table 24: North America Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
  - Table 25: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 26: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 27: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 28: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Table 29: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Table 30: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Table 31: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 32: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 33: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Table 34: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Table 35: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Table 36: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 37: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Table 38: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Table 39: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Table 40: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Table 41: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Table 42: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
  - Table 43: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
  - Table 44: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
  - Table 45: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
  - Table 46: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 47: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 48: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 49: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Table 50: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Table 51: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Table 52: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 53: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 54: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Table 55: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Table 56: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Table 57: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 58: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Table 59: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Table 60: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Table 61: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Table 62: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Table 63: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
  - Table 64: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
  - Table 65: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
  - Table 66: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
  - Table 67: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 68: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 69: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 70: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Table 71: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Table 72: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Table 73: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 74: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 75: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Table 76: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Table 77: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Table 78: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 79: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Table 80: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Table 81: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Table 82: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Table 83: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Table 84: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
  - Table 85: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
  - Table 86: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
  - Table 87: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
  - Table 88: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 89: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 90: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 91: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Table 92: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Table 93: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Table 94: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 95: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 96: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Table 97: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Table 98: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Table 99: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 100: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Table 101: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Table 102: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Table 103: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Table 104: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
  - Table 105: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
  - Table 106: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
  - Table 107: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
  - Table 108: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
  - Table 109: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 110: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 111: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 112: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
  - Table 113: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
  - Table 114: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
  - Table 115: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 116: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 117: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
  - Table 118: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
  - Table 119: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
  - Table 120: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 121: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
  - Table 122: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
  - Table 123: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
  - Table 124: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
  - Table 125: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
- Sanofi SA
- Novartis AG Company Profile
- Endo International Plc
- CMP Pharma Inc.
- STI Pharma LLC
- Akorn Incorporated
- Lupin Ltd Company Profile
- Johnson & Johnson Services Inc.
- Macleods Pharmaceuticals Ltd.
- Pfizer Inc Company Profile
- Hikma Pharmaceuticals PLC
Settings

Related Reports

Our Clients

Inquiry Before Buying

Drug-Resistant Tuberculosis Treatment Market

Report ID 84849
Published Date Feb 2024
Rating
- ★★★★★
  
  ★★★★★
- (104)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)